

Cases from the Community: Clinical Investigators Provide Perspectives
on Actual Patients with Pancreatic Cancer – Audio Program

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to the 2018 ASCO Clinical Practice Guideline Update, the preferred treatment for metastatic pancreatic cancer in patients who experience disease progression after receiving first-line FOLFIRINOX is _____.
 - a. Gemcitabine with *nab* paclitaxel
 - b. Nal-IRI/5-FU/leucovorin
 - c. Gemcitabine
2. Data from randomized clinical trials support the use of _____ as second-line therapy for patients with metastatic pancreatic cancer after disease progression on a gemcitabine-based regimen.
 - a. FOLFIRI
 - b. Nal-IRI
 - c. Nal-IRI/5-FU/leucovorin
3. The ongoing AFACT trial is comparing *nab* paclitaxel and gemcitabine to gemcitabine alone for patients with pancreatic cancer in which setting?
 - a. Neoadjuvant
 - b. Adjuvant
 - c. Metastatic
4. Side effects associated with FOLFIRINOX include _____.
 - a. Fatigue
 - b. Myelosuppression
 - c. Neuropathy
 - d. All of the above
5. The ongoing Phase III POLO trial is evaluating maintenance therapy with _____ versus placebo for patients with pancreatic cancer and BRCA mutations whose disease has not progressed on first-line platinum-based chemotherapy.
 - a. Rucaparib
 - b. Olaparib
 - c. Niraparib